Lv2
200 积分 2025-08-07 加入
TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis
1天前
已完结
Neutrophil‐to‐lymphocyte and hypopharyngeal cancer prognosis: System review and meta‐analysis
25天前
已完结
Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article
1个月前
已完结
Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes
1个月前
已完结
Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data
3个月前
已完结
Gaining Insight Into Ondansetron Safety in Early Pregnancy
3个月前
已完结
Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event reporting System (FAERS) database: A real-world pharmacovigilance study
3个月前
已完结
A real-world drug safety surveillance study of lenvatinib from the FAERS database
3个月前
已完结
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab
3个月前
已完结
Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA adverse event reporting system
3个月前
已完结
皖公网安备34019202002308
